Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian 350028

3 studies enrolling now · 10 studies all time

What they study most

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, Advanced MTAP-null Solid Tumors, Advanced Solid Tumor, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma, MTAP-deleted NSCLC, Metastatic Hepatocellular Carcinoma, Non-small Cell Lung Cancer, PBC

Studies at this site

• A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis — Recruiting now
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) — Running, not enrolling
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) — Running, not enrolling
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). — Running, not enrolling
• A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) — Running, not enrolling
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) — Running, not enrolling
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Running, not enrolling
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Running, not enrolling